SVCM
Saturn V Capital Management Portfolio holdings
AUM
$247M
This Quarter Return
+15.33%
1 Year Return
+2.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$280M
AUM Growth
+$280M
(+5.7%)
Cap. Flow
-$8.67M
Cap. Flow
% of AUM
-3.1%
Top 10 Holdings %
Top 10 Hldgs %
70.61%
Holding
30
New
4
Increased
13
Reduced
8
Closed
5
Top Buys
| 1 |
CG Oncology
CGON
|
$19.6M |
| 2 |
MoonLake Immunotherapeutics
MLTX
|
$15.1M |
| 3 |
Ascendis Pharma
ASND
|
$13M |
| 4 |
SLN
Silence Therapeutics
SLN
|
$8.75M |
| 5 |
Phathom Pharmaceuticals
PHAT
|
$5.09M |
Top Sells
| 1 |
argenx
ARGX
|
$22.8M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
$18.9M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$9.92M |
| 4 |
Amicus Therapeutics
FOLD
|
$7.08M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$6.62M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma
ASND
$11.8B
| $29.9M | 10.69% |
200,285
+87,061
| +77% | +$13M |
|
2
Disc Medicine
IRON
$2.07B
| $25.1M | 8.98% |
511,041
+7,952
| +2% | +$391K |
|
3
Vaxcyte
PCVX
$4B
| $23.4M | 8.37% |
204,987
-10,693
| -5% | -$1.22M |
|
|
4
CG Oncology
CGON
$2.04B
| $19.6M | 7.01% |
+520,119
| New | +$19.6M |
|
5
Cogent Biosciences
COGT
$1.69B
| $18.5M | 6.61% |
1,712,899
+38,980
| +2% | +$421K |
|
|
CRGX
6
DELISTED
CARGO Therapeutics
CRGX
| $18.5M | 6.61% |
1,002,461
+145,612
| +17% | +$2.69M |
|
7
Cytokinetics
CYTK
$4.23B
| $17.5M | 6.25% |
331,283
+59,247
| +22% | +$3.13M |
|
|
8
Phathom Pharmaceuticals
PHAT
$864M
| $15.8M | 5.65% |
874,590
+281,284
| +47% | +$5.09M |
|
|
9
MoonLake Immunotherapeutics
MLTX
$3.54B
| $15.1M | 5.39% |
+298,974
| New | +$15.1M |
|
10
Celcuity
CELC
$2.17B
| $14.1M | 5.04% |
946,335
+185,394
| +24% | +$2.76M |
|
|
11
argenx
ARGX
$43.6B
| $12M | 4.28% |
22,111
-42,085
| -66% | -$22.8M |
|
12
Syndax Pharmaceuticals
SNDX
$1.41B
| $9.66M | 3.45% |
501,978
+82,324
| +20% | +$1.58M |
|
|
SLN
13
Silence Therapeutics
SLN
$227M
| $8.75M | 3.13% |
+481,127
| New | +$8.75M |
|
|
ABVX
14
Abivax
ABVX
$6.12B
| $7.47M | 2.67% |
648,019
+20,259
| +3% | +$233K |
|
|
INZY
15
DELISTED
Inozyme Pharma
INZY
| $7.16M | 2.56% |
1,368,810
+228,500
| +20% | +$1.2M |
|
16
Merus
MRUS
$4.98B
| $6.56M | 2.34% |
131,240
-33,533
| -20% | -$1.68M |
|
|
17
KalVista Pharmaceuticals
KALV
$678M
| $6.44M | 2.3% |
556,489
-571,989
| -51% | -$6.62M |
|
18
Neumora Therapeutics
NMRA
$280M
| $5.72M | 2.04% |
432,996
+42,912
| +11% | +$567K |
|
|
19
Crinetics Pharmaceuticals
CRNX
$2.92B
| $5.6M | 2% |
109,567
-370,114
| -77% | -$18.9M |
|
20
Ironwood Pharmaceuticals
IRWD
$214M
| $4.62M | 1.65% |
1,120,409
+6,585
| +0.6% | +$27.1K |
|
|
21
BioMarin Pharmaceuticals
BMRN
$11.2B
| $2.63M | 0.94% |
37,432
-141,157
| -79% | -$9.92M |
|
22
iTeos Therapeutics
ITOS
| $2M | 0.71% |
195,704
-171,725
| -47% | -$1.75M |
|
|
CTNM
23
Contineum Therapeutics
CTNM
$293M
| $1.48M | 0.53% |
77,297
+4,466
| +6% | +$85.5K |
|
24
ArriVent BioPharma
AVBP
$776M
| $1.11M | 0.4% |
+47,266
| New | +$1.11M |
|
|
LBPH
25
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $1.05M | 0.38% |
31,529
-39,913
| -56% | -$1.33M |
|